Study on the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Steroid - Dependent /Steroid-resistant Nephrotic Syndrome in Children

Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age2-18
SponsorZhang Ting

About this trial

The objective of this clinical trial was to understand whether FMT is effective in treating steroid-dependent/steroid-resistant nephrotic syndrome in children. It will also learn about the safety of FMT. The main question it was designed to answer was: Did FMT reduce participants '24-hour urine protein content? What medical problems did participants experience while using FMT? The researchers will compare FMT treatment with and without FMT on top of conventional treatment to see if FMT is effective in treating steroid-dependent/steroid-resistant nephrotic syndrome in children. Participants will receive 2 FMT treatments, 1 endoscopic injection under anesthesia, 1 oral fecal bacteria transplantation capsule intake, and follow-up visits (weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48) every 4 weeks from the beginning of medication to our renal specialist clinic for drug efficacy evaluation and safety testing. Blood and fecal samples were collected to determine the effects of fecal bacterial transplantation on intestinal flora, fecal metabolomics, and intestinal mucosal permeability.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 2-18 years, steroid-dependent/steroid-resistant nephrotic syndrome, regardless of gender, with SDNS at steroid-dependent doses less than 0.5 mg/kg.d

Disqualifiers

Those with concurrent infections or diseases of other organ systems, and those with abnormal renal function.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Fecal microbiota transplantation (FMT)

    Drug

    FMT was slowly administered to the patient's small intestine with fecal suspension under anesthesia and patients received a second transplant through oral administration freeze-dried capsules containing the fecal matter.

Treatment groups

120 Participants
are divided into 4 treatment groups
Group A: SDNS:control groupNo intervention 0 interventions
Group B: SDNS:Fecal microbiota transplantation groupExperimental treatment 1 intervention
Group C: SRNS control groupNo intervention 0 interventions
Group D: SRNS:Fecal microbiota transplantation groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

24h urinary protein

24-hour urine protein by urine collection

Time frame
follow-up visits (weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48) every 4 weeks from the beginning of medication to our renal specialist clinic for drug efficacy evaluation and safety testing
2

Gut microbiota

Collect fecal samples

Time frame
immediately Before FMT, immediately before second FMT, one month after second FMT
3

Zonulin

collect blood samples

Time frame
immediately Before FMT, immediately before second FMT, one month after second FMT

Secondary outcomes

1

Serum creatinine

collect blood samples

Time frame
immediately Before FMT, immediately before second FMT, one month after second FMT

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Zhang Ting

Lead sponsor

Shanghai Children's Hospital

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: